Twenty-five-year Experience With the Medtronic-Hall Valve Prosthesis (Hall-Kaster)

This study has been completed.
Sponsor:
Information provided by:
Oslo University Hospital
ClinicalTrials.gov Identifier:
NCT00486928
First received: June 14, 2007
Last updated: July 22, 2011
Last verified: July 2011

June 14, 2007
July 22, 2011
May 2004
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00486928 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Twenty-five-year Experience With the Medtronic-Hall Valve Prosthesis
Twenty-five-year Experience With the Medtronic-Hall Valve Prosthesis

Background-:. The Medtronic-Hall (MH) valve was developed and for the first time implanted in Oslo in 1977. A total of 1,104 patients received this valve at Rikshospitalet-Radiumhospitalet HF in the period 1977-87. In the present study we followed all 816 patients undergoing aortic valve replacement (AVR) over a 25-year period.

The Medtronic-Hall (MH) tilting valve disk was first implanted in Oslo in June 1977. From 1977 through 1987, the valve was used as the only valve of choice and inserted in a total of 1,104 consecutive patients at our department.

The MH valve is made of a single piece of titanium with no welds. The disk is made of tungsten impregnated graphite with a carbon pyrolytic coating. The tungsten renders the disk radiopaque. In the aortic position the maximal opening is 75˚. A central aperture in the disk allows free rotation. The valve is rotatable in the sewing ring. The sewing ring is made of Teflon. Aortic sizes are 20-31 mm (outer diameter).

The initial clinical results were published in 1979 (1). The cohort of patients has been followed-up and analysed at 5, 10 and 15 years (2-5). In the present study we report our 25-year follow-up data for the 816 patients undergoing aortic valve replacement (AVR) with special reference to survival, functional status, valve-related complications and the impact of concomitant surgery.

Observational
Observational Model: Cohort
Time Perspective: Retrospective
Not Provided
Not Provided
Probability Sample

All consecutive patients undegoing AVR during inclusion period

Aortic Valve Disease
Not Provided
AVR
All consecutive patients in the study period
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
816
May 2005
Not Provided

Inclusion Criteria:

  • All patients with aortic valve replacement 1977-87
Both
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
Norway
 
NCT00486928
06/8009
No
Not Provided
Oslo University Hospital
Not Provided
Principal Investigator: Jan L Svennevig, MD,PhD Rikshospitalet, Oslo
Oslo University Hospital
July 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP